TABLE 3.

Clinical characteristics and outcomes of women who have been prescribed HT for the past year compared with those who did not using age-matched case-control data with a 1:3 ratio

Variables	HT recent users (n = 53)	HT never users (n = 159)	P value
Age, y	49.40 ± 11.04	49.40 ± 10.97	0.925
Comorbidities, no. (%)
Cardiovascular disease	.	.	NA
Cerebrovascular disease	.	.	NA
Hypertension	5 (9.43)	17 (10.69)	0.795
Heart failure	0	6 (3.77)	0.151
Diabetes	4 (7.55)	11 (6.92)	0.877
Pulmonary disease	5 (9.43)	15 (9.43)	>0.999
Malignancy	1 (1.89)	0	0.250
Chronic kidney disease	0	3 (1.89)	0.314
Chronic liver disease	.	.	NA
Treatments, no. (%)
Oxygen therapy	1 (1.89)	10 (6.29)	0.211
Invasive mechanical ventilation	0	2 (1.26)	0.412
Extracorporeal membrane oxygenation	0	1 (0.63)	0.563
Renal replacement therapy	0	1 (0.63)	0.563
Clinical outcomes
ICU admission, no. (%)	2 (3.77)	6 (3.77)	>0.999
Length of ICU stay, d	19.0 ± 15.56	15.67 ± 7.87	0.210
Length of hospital stay for admitted patients, d	6.89 ± 8.65	6.91 ± 9.11	0.677
Mortality	0	1 (0.63)	0.563

HT, hormone therapy; ICU, intensive care unit.